close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

501.44 -3.29 (-0.65%)
Delayed Quote Updated: 2:45 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
News headline image
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Large-Cap Stocks to Research Further and 1 We Question
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m... 
Via StockStory
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗
Via Chartmill
News headline image
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide ↗
Inflation affects corporations differently. These two have the tools to navigate the challenge better than most. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? ↗
Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ ↗
CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER). 
Via Benzinga
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Don't bet against Vertex Pharmaceuticals in cystic fibrosis. 
Via The Motley Fool
News headline image
3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ... 
Via StockStory
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool
News headline image
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $3.3 billion with guidance raised on strong newer product growth. 
Via The Motley Fool
Topics Earnings
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfol... 
Via StockStory
Topics Earnings
News headline image
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗
This risk is weighing on the stock. 
Via The Motley Fool
News headline image
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday ↗
The company notched a pair of modest beats in its second quarter. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Q2 Earnings Call Highlights ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising... 
Via MarketBeat
Topics Earnings
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ... 
Via StockStory
News headline image
Vertex Reports Second Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be... 
Via StockStory
Topics Artificial Intelligence
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
The next six months may be decisive for the biotech. 
Via The Motley Fool
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Competitive Advantages
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.